Tenderwize
Retour à la recherche

Open house discount agreements Erythropoietin zeta

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jun 03, 2027 · 278 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin zeta, ATC B03AX01

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated value or volume is provided. It is impossible to assess the potential revenue from this agreement.

This is an open-house model, not a standard procurement. The buyer states it is not subject to procurement law. Legal r...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jul 2027
  • Non-exclusive discount agreements for the pharmaceutical product Erythropoietin zeta (ATC B03AX01) in Germany (Bavaria region).
  • Contracts are for two years from 01.08.2025 to 31.07.2027.
Afficher le résumé complet

This is an open-house model (not a standard procurement procedure) by AOK Bayern for non-exclusive discount agreements on the active substance Erythropoietin zeta (ATC B03AX01). Any interested pharmaceutical company meeting the eligibility criteria can join. Contracts run from 01.08.2025 to 31.07.2027. No estimated value is provided. Submission is via paper or electronic qualified signature. The procedure is open to all qualified pharmaceutical companies.

Risques

No estimated value or volume is provided. It is impossible to assess the potential revenue from this agreement.

This is an open-house model, not a standard procurement. The buyer states it is not subject to procurement law. Legal r...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible.

Administrative

  • Must submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Contracts must be signed and submitted in two copies if by paper, or electronically with qualified electronic signature.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria; all eligible companies are accepted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open house discount agreements Erythropoietin zeta

Non-exclusive discount agreements for Erythropoietin zeta (ATC B03AX01). Contracts are identical and non-negotiable. The lot covers the entire scope of the open-house model.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jul 2025 - Jul 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria; all eligible companies are accepted.

Date limite

Deadline Jun 03, 2027

Détails de la procédure

Date de publication
15 Jun 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
385986-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30